ClinicalTrials.gg
RecruitingNCT05906056CPMversusHOUpdated Dec 6, 2024

Continuous Passive Motion Versus Heterotopic Ossification

An interventional study of Continuous Passive Motion (CPM) and Conventional physiotherapy (PT) in Traumatic Brain Injury, Spinal Cord Injuries and Stroke, sponsored by University of Ioannina. Recruiting at 1 site in Greece. Open to participants aged 15 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-12-06.

Sponsored by University of Ioannina · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
15 Years to 70 Years
Sex
All
01

Study summary

The investigators hypothesize that Heterotopic Ossification (HO) formation can be suppressed if the application of a Continuous Passive Motion (CPM) device can be performed for a substantial amount of time. The investigators will use the following study design: a pilot study with 10 ICU patients receiving CPM and 10 matched cases which will follow a conventional physiotherapy program at the time of the conduction of the study. The comparison between the treatment and referent groups of the outcomes will prove the prophylactic power of CPM against HO.

Read the detailed description

The aim of this study is to formally evaluate whether the investigators can indeed prevent HO by the timely and painless use of CPM in neurogenic intensive care unit (ICU) patients with stabilized medical conditions, suffering from neurological insults either traumatic brain injury (TBI), stroke, or Spinal Cord Injury (SCI). The investigators hypothesize that HO formation can be suppressed if CPM can be performed for a substantial amount of time. The investigators will perform a pilot study with 10 ICU patients receiving CPM and 10 matched cases which will follow a conventional physiotherapy program at the time of the conduction of the study. The primary outcomes will be the CT appearance of HO in the hip or knee joint and the degree of ROM limitation in the given joint at baseline and at the end of the clinical trial. A secondary outcome that will be measured, will be the Glasgow Coma Scale (GCS) at the beginning and at the end of the CPM program. The comparison between the treatment and referent groups in terms of these outcomes will prove the prophylactic power of CPM against HO.

02

Conditions studied

  • Traumatic Brain Injury
  • Spinal Cord Injuries
  • Stroke

Keywords

  • Ossification, Heterotopic
  • continuous passive motion (CPM)
  • zoledronic acid
  • range of motion (ROM)
  • PROPHYLAXIS
03

In context

Brain Injuries, Traumatic

1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

This study's planned enrollment of 20 is below the median of 52 across 1,091 interventional studies indexed under Brain Injuries, Traumatic.

Browse Brain Injuries, Traumatic studies →

Lead sponsor

University of Ioannina is the lead sponsor of 53 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with stabilized medical condition suffering from neurological insult either traumatic brain injury (TBI), stroke, or Spinal Cord Injury.
  2. A negative triplex ultrasound in order to rule out deep venous thrombosis (DVT)
  3. A positive three-phase bone scan with Tc99. (Will be obtained as soon as HO symptoms are onset.)
  4. Patients with verified HO formation on the knee or hip joint will undergo a CT to show the extent of the lesion.

Exclusion criteria

Exclusion Criteria:

  1. Life-threatening conditions that render Continuous passive motion (CPM) application difficult.
  2. HO detected in another location than the hip or knee joint.
  3. Concomitantly presence of other fractures that will interfere with the bone alkaline phosphatase (AP) level.
  4. Patients not reacting to painful stimuli
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Continuous passive motion (CPM)

    10 ICU patients receiving CPM at HO joints that continuously stretches slowly the joint passively at a constant velocity in a painless range and for a substantial amount of time until there is evidence both laboratory (bone alkaline phosphatase) and radiographically (CT), that osteogenesis has entered a quiescent state. Conventional PT will also be performed. Plus a single dose of zoledronic acid (Aclasta) once the diagnosis of HO is made.

    Device: Continuous Passive Motion (CPM) · Other: Conventional physiotherapy (PT) · Drug: Zoledronic Acid Injection

  • Active comparator
    Physiotherapy (PT)

    10 ICU patients receiving the conventional PT, plus a single dose of zoledronic acid (Aclasta) once the diagnosis of HO is made.

    Other: Conventional physiotherapy (PT) · Drug: Zoledronic Acid Injection

Interventions

  • DeviceContinuous Passive Motion (CPM)

    CPM uses machines to move a joint passively i.e. without the patient exerting any effort. A motorized device moves the joint repetitively to a set of degrees and movement speed, determined by the caregiver either a medical doctor (physiatrist or orthopedic surgeon) or a physiotherapist. Its action preserves the joint's range of motion (ROM)

  • OtherConventional physiotherapy (PT)

    Daily passive range of motion exercises (ROM) performed by the physiotherapist of the intensive care unit (ICU)

  • DrugZoledronic AcidStudies of Zoledronic AcidZoledronic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    one dose of intravenous zoledronic acid will be administered

06

What researchers measure

Primary outcomes

  1. ROM lost during the trial

    The difference in ROM between the measurements at baseline and at the end of the The program will last until there is evidence by CT and laboratory measurements (bone Alkaline Phosphatase) that osteogenesis has entered a quiescent state. prophylactic program

    Time frame: According to the literature it is estimated to last approx. 70 days

  2. HO appearance on CT

    Based on Brooker HO classification method (between I and IV with IV being bridging bone and joint ankylosis), the difference in CT appearance at baseline and at the end of the program will serve as a descriptive tool. Until there is evidence by CT and laboratory measurements (bone Alkaline Phosphatase) that osteogenesis has entered a quiescent state.

    Time frame: According to the literature it is estimated to last approx. 70 days

Secondary outcomes

  1. Patient's Glasgow Coma Scale (GCS)

    Calculation of GCS (range 0-15 with 15 being the normal) at the beginning and at the end of the CPM program.Until there is evidence by CT and laboratory measurements (bone Alkaline Phosphatase) that osteogenesis has entered a quiescent state.

    Time frame: According to the literature it is estimated to last approx. 70 days

07

Study locations

1 of 1 sites recruiting
  • Department of Physical and Rehabilitation Medicine
    Ioánnina, Epirus 45110, Greece
    Recruiting
08

References and documents

Publications

  • Scalzitti DA. Because of the risk of developing heterotopic ossification, are passive range of motion exercises contraindicated following traumatic injuries? Phys Ther. 2003 Jul;83(7):659-7. No abstract available. PubMed 12872776 ↗
  • Vasileiadis GI, Varvarousis DN, Manolis I, Ploumis A. The Impact of Continuous Passive Motion on Heterotopic Ossification Maturation. Am J Phys Med Rehabil. 2021 Dec 1;100(12):e194-e197. doi: 10.1097/PHM.0000000000001852. PubMed 34310347 ↗
  • Vasileiadis GI, Balta AA, Zerva A, Kontogiannopoulos V, Varvarousis DN, Dimakopoulos G, Ploumis A. Role of Kinesiotherapy in the Prevention of Heterotopic Ossification: A Systematic Review. Am J Phys Med Rehabil. 2023 Feb 1;102(2):110-119. doi: 10.1097/PHM.0000000000002043. Epub 2022 Apr 28. PubMed 35512120 ↗
  • Genet F, Chehensse C, Jourdan C, Lautridou C, Denormandie P, Schnitzler A. Impact of the operative delay and the degree of neurologic sequelae on recurrence of excised heterotopic ossification in patients with traumatic brain injury. J Head Trauma Rehabil. 2012 Nov-Dec;27(6):443-8. doi: 10.1097/HTR.0b013e31822b54ba. PubMed 22495100 ↗
  • van Kampen PJ, Martina JD, Vos PE, Hoedemaekers CW, Hendricks HT. Potential risk factors for developing heterotopic ossification in patients with severe traumatic brain injury. J Head Trauma Rehabil. 2011 Sep-Oct;26(5):384-91. doi: 10.1097/HTR.0b013e3181f78a59. PubMed 21321512 ↗
  • Citak M, Suero EM, Backhaus M, Aach M, Godry H, Meindl R, Schildhauer TA. Risk factors for heterotopic ossification in patients with spinal cord injury: a case-control study of 264 patients. Spine (Phila Pa 1976). 2012 Nov 1;37(23):1953-7. doi: 10.1097/BRS.0b013e31825ee81b. PubMed 22614800 ↗
  • Shehab D, Elgazzar AH, Collier BD. Heterotopic ossification. J Nucl Med. 2002 Mar;43(3):346-53. PubMed 11884494 ↗
  • Holguin PH, Rico AA, Garcia JP, Del Rio JL. Elbow anchylosis due to postburn heterotopic ossification. J Burn Care Rehabil. 1996 Mar-Apr;17(2):150-4. doi: 10.1097/00004630-199603000-00009. PubMed 8675505 ↗
  • Linan E, O'Dell MW, Pierce JM. Continuous passive motion in the management of heterotopic ossification in a brain injured patient. Am J Phys Med Rehabil. 2001 Aug;80(8):614-7. doi: 10.1097/00002060-200108000-00013. PubMed 11475483 ↗
  • Stover SL, Hataway CJ, Zeiger HE. Heterotopic ossification in spinal cord-injured patients. Arch Phys Med Rehabil. 1975 May;56(5):199-204. PubMed 806274 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Apr 2026, 35 months after the start.

Of 445 non-industry interventional studies with no phase under Brain Injuries, Traumatic, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 64. This study's planned 35 months is below that.

Counting every sponsor, half of 467 studies reached it within 41 months; a quarter within 22 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2023
First posted
Jun 15, 2023
StartActual
May 12, 2023
Primary completionEst.
Apr 25, 2026
CompletionEst.
Mar 25, 2027
Last update
Dec 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05906056
Lead sponsor
University of Ioannina
Responsible party
Avraam Ploumis (Professor of Phyical and Rehabilitation Medicine, University of Ioannina) — Principal investigator
First posted
Jun 15, 2023
Start date
May 12, 2023
Primary completion
Apr 25, 2026 (estimated)
Completion
Mar 25, 2027 (estimated)
Last update
Dec 6, 2024

Study contacts

Avraam Ploumis, MD, PhD
Contact
aploumis@uoi.gr
+ 30 693 2080701
George I Vasileiadis, MD, PhD
Contact
givasileiadis@gmail.com
+ 30 694 5789239

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion